In this context, all biotherapies on the market in the USA and Europe have also been associated with neutropenia (especially well-documented for TNF-α inhibitors, tocilizumab, rituximab, and alemtuzumab) as described above (Table 1) [14,15,16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43]. The gene discussed is TNF; the disease is neutropenia.